Belotecan Polypeptide Conjugate for Tumor-Selective Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Belotecan, a synthetic water-soluble camptothecin analogue, exhibits extensive antitumor activity but is limited in clinical applications due to significant side effects such as neutropenia, thrombocytopenia, anaemia, diarrhea, and gastrointestinal toxicity, and lacks targeted delivery in cancer therapy.
Innovation Solution
A tumor-targeting activated polypeptide conjugate is developed, specifically designed to be selectively released in the tumor microenvironment, reducing toxicity and enhancing targeting efficacy, allowing for larger doses to be used clinically.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Belotecan is used as an antitumor drug, then antitumor activity is improved, but side effects and toxicity increase
Solution Approach 1:
The patent introduces a polypeptide conjugate as an intermediary carrier that delivers Belotecan specifically to tumor cells. The conjugate consists of a polypeptide chain with a drug-binding site that selectively binds to tumor cell surface receptors, acting as a mediator between the drug and target cells to achieve targeted delivery and reduce off-target toxicity.
Solution Approach 2:
The patent applies local quality by designing a polypeptide conjugate with specific binding characteristics that are different from normal cells. The conjugate has a defined polypeptide sequence and structure that enables selective interaction with tumor cell surface receptors, creating a localized effect at the tumor site while sparing normal tissues.
2Adaptability or versatility
If Belotecan is administered systemically, then tumor coverage is improved, but targeting precision deteriorates
Solution Approach 1:
The polypeptide conjugate serves as a targeted intermediary that circulates in the bloodstream and selectively interacts with tumor cell surface receptors. This mediator approach allows the drug to reach tumors while maintaining precision in targeting, as the conjugate's polypeptide structure is designed to recognize specific tumor-associated markers.
3Reliability
If higher doses of Belotecan are used, then therapeutic effect is improved, but toxicity increases
Solution Approach 1:
The polypeptide conjugate acts as a protective intermediary that prevents direct exposure of normal tissues to high doses of Belotecan. By delivering the drug through the conjugate to tumor cells, the system can administer higher total doses while maintaining lower local concentrations in normal tissues, thus improving therapeutic effect without proportionally increasing toxicity.
Data Source
AI summary
The present disclosure provides a polypeptide conjugate and a use thereof, and particularly relates to a Belotecan drug and derivative polypeptide conjugate drugs thereof. The polypeptide conjugate drugs provided by the present disclosure are selectively released in a tumor microenvironment, which can solve the problem of limited clinical use due to the non-targeting property and significant side effects of the Belotecan drug in the prior art. Clinically, greater doses can be used to treat cancers and improve the overall therapeutic effect.